282 related articles for article (PubMed ID: 35063964)
1. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H; Tsukada Y; Inamori K; Togashi Y; Koyama S; Kotani D; Fukuoka S; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Wakabayashi M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Suzuki Y; Sato A; Nishikawa H; Ito M; Yoshino T
Clin Cancer Res; 2022 Mar; 28(6):1136-1146. PubMed ID: 35063964
[TBL] [Abstract][Full Text] [Related]
2. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer.
Bando H; Tsukada Y; Ito M; Yoshino T
Clin Colorectal Cancer; 2022 Mar; 21(1):3-9. PubMed ID: 34776358
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review.
Mori R; Uemura M; Sekido Y; Hata T; Ogino T; Takahashi H; Miyoshi N; Mizushima T; Doki Y; Eguchi H
World J Surg Oncol; 2022 May; 20(1):166. PubMed ID: 35619103
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis.
O'Connell E; Reynolds IS; McNamara DA; Prehn JHM; Burke JP
Surg Oncol; 2020 Sep; 34():57-62. PubMed ID: 32891354
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.
Tojo M; Horie H; Koinuma K; Miyato H; Tsukui H; Kaneko Y; Futoh Y; Kimura Y; Takahashi K; Saito A; Ohzawa H; Yamaguchi H; Lefor AK; Sata N; Kitayama J
Colorectal Dis; 2022 Oct; 24(10):1140-1149. PubMed ID: 35502766
[TBL] [Abstract][Full Text] [Related]
6. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
7. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
8. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
10. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.
Xiao W; Luo H; Yao Y; Wang Y; Liu S; Sun R; Chen G
Front Immunol; 2023; 14():1149122. PubMed ID: 37033988
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
12. Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Nakao T; Kashihara H; Wada Y; Yoshimoto T; Okikawa S; Yamashita S; Shimada M
BMC Cancer; 2022 Dec; 22(1):1263. PubMed ID: 36471264
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.
Lee JH; Kang BH; Song C; Kang SB; Lee HS; Lee KW; Chie EK; Kim JS
In Vivo; 2020; 34(4):2119-2126. PubMed ID: 32606192
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract][Full Text] [Related]
15. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
16. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
[TBL] [Abstract][Full Text] [Related]
17. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
18. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M; Vanoni G; Loap P; Dubot C; Timperi E; Minsat M; Bazire L; Durdux C; Fourchotte V; Laas E; Pouget N; Castel-Ajgal Z; Marret G; Lesage L; Meseure D; Vincent-Salomon A; Lecompte L; Servant N; Vacher S; Bieche I; Malhaire C; Huchet V; Champion L; Kamal M; Amigorena S; Lantz O; Chevrier M; Romano E
Nat Commun; 2023 Jun; 14(1):3698. PubMed ID: 37349318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
